Filed Pursuant to Rule 424(b)(3)
Registration No. 333-273536
GDEV INC.
12,499,993 ORDINARY SHARES
This prospectus relates to the issuance from time to time by GDEV Inc. (formerly, Nexters Inc.) (together with its subsidiaries, the “Company,” the “Group,” “we,” “us,” or “our”) of up to 12,499,993 of our ordinary shares, no par value per share (the “ordinary shares”), that are issuable upon exercise of 12,499,993 of our public warrants. Each whole public warrant entitles the holder thereof to purchase one ordinary share at a price of $11.50 per ordinary share, subject to adjustment as described in this prospectus, and only whole warrants are exercisable.
On August 26, 2021, we consummated the transactions (the “Transactions”) contemplated by that certain Business Combination Agreement (the “Business Combination Agreement”), dated as of January 31, 2021, as amended on July 17, 2021 and August 11, 2021, by and among GDEV Inc. (formerly, Nexters Inc.) (“GDEV” or the “Issuer”), Kismet Acquisition One Corp. (“Kismet”), Kismet Sponsor Limited (the “Sponsor”), solely in its capacity as Kismet’s representative, Nexters Global Ltd. (“Nexters Global”), Fantina Holdings Limited, a private limited liability company domiciled in Cyprus, solely in its capacity as the representative of the shareholders of Nexters Global, and the shareholders of Nexters Global party thereto. As contemplated by the Business Combination Agreement, Kismet was merged into the Issuer, with the Issuer surviving the merger and the securityholders of Kismet (other than those who elected to redeem their Kismet ordinary shares) becoming securityholders of the Issuer (the “Merger”), and the Issuer acquired all of the issued and outstanding share capital of Nexters Global from the holders of Nexters Global’s share capital for a combination of cash and GDEV ordinary shares, such that Nexters Global became a direct wholly owned subsidiary of the Issuer (the “Share Acquisition”). Pursuant to the Business Combination Agreement, upon consummation of the Merger, each outstanding public warrant of Kismet was converted automatically into the right of the holder thereof to receive one public warrant of the Issuer having, and being subject to, substantially the same terms and conditions as the Kismet public warrants.
Upon Kismet’s initial public offering (the “IPO”), the Sponsor held an aggregate of 6,750,000 Kismet founder shares which it had acquired against a capital contribution of $25,000, representing an acquisition price of approximately $0.0037 per share. In the IPO, Kismet issued 25,000,000 units to public holders at a price of $10.00 per unit, with each unit consisting of one Kismet ordinary share and one-half of one Kismet warrant. Simultaneously with the consummation of the IPO, the Sponsor purchased 6,750,000 Kismet private placement warrants at a purchase price of $6,750,000, or $1.00 per private placement warrant. Upon the consummation of the Transactions, (i) the Sponsor’s 6,750,000 Kismet founder shares were converted into 6,750,000 GDEV ordinary shares, (ii) 3,188,758 Kismet ordinary shares issued to public holders (following the redemption of 21,811,242 Kismet ordinary shares prior to the Merger) were converted to 3,188,758 GDEV ordinary shares, (iii) the Sponsor’s 6,750,000 Kismet private placement warrants were converted into 6,750,000 GDEV private placement warrants, (iv) the Sponsor acquired, pursuant to the A&R Forward Purchase Agreement, 5,000,000 GDEV ordinary shares and 1,000,000 GDEV warrants for an aggregate purchase price of $50,000,000, or approximately $9.86 per GDEV ordinary share and approximately $0.72 per GDEV warrant (assuming an estimated purchase price allocation based upon the closing trading price of Kismet’s public warrants of $0.72 on August 27, 2021, the closing date of the Transactions), and (v) the Sponsor transferred, pursuant to the PIPE Subscription Agreements, 1,625,000 GDEV private placement warrants to the PIPE Investors, for which the Sponsor did not receive any consideration.
Pursuant to other registration statements we have filed with the Securities and Exchange Commission, we have registered for resale by certain selling securityholders up to 222,516,619 ordinary shares and up to 7,750,000 warrants. Furthermore, as of the date of this prospectus, 9,562,757 ordinary shares are registered and subject to issuance under our 2021 Employee Stock Option Plan, which ordinary shares may, upon their issuance, be resold in the public market. In aggregate, the percentage of our ordinary shares being offered for resale under both this prospectus and our other registration statements amounts to approximately 98.9% of our shares outstanding on a fully diluted basis assuming both (a) the exercise of all outstanding warrants and the exercise of all options vested as of the date of this prospectus or within 60 days hereof and (b) the issuance of all ordinary shares issuable under our 2021 Employee Stock Option Plan (excluding ordinary shares associated with such vested options). Given the substantial number of ordinary shares registered for potential resale by those selling securityholders, the sale of ordinary shares by those selling securityholders, or the perception in the market that the selling securityholders of a large number of shares intend to sell shares, could increase the volatility of the market price of our ordinary shares or result in a significant decline in the public trading price of our ordinary shares. Even if our trading price is significantly below $10.00, the offering price of the Kismet units offered in its IPO, the Sponsor, one of those selling securityholders, may still have an incentive to sell our ordinary shares because it acquired 6,750,000 ordinary shares relating to the 6,750,000 Kismet founder shares at prices lower than the public investors or the last reported trading price of our ordinary shares. For example, based on the last